Literature DB >> 1707982

Characterization and sequence analyses of antibody-selected antigenic variants of herpes simplex virus show a conformationally complex epitope on glycoprotein H.

U A Gompels1, A L Carss, C Saxby, D C Hancock, A Forrester, A C Minson.   

Abstract

Thirteen antigenic variants of herpes simplex virus which were resistant to neutralization by monoclonal antibody 52S or LP11 were isolated and characterized. The antibodies in the absence of complement potently neutralize infectivity of wild-type virus as well as inhibit the transfer of virus from infected to uninfected cells ("plaque inhibition") and decrease virus-induced cell fusion by syncytial strains. The first variant isolated arose in vivo. Of 66 type 1 isolates analyzed from typing studies of 100 clinical isolates, one was identified as resistant to neutralization by LP11 antibody. The glycoprotein H (gH) sequence was derived and compared with those of wild-type and syncytial laboratory strains SC16, strain 17, and HFEM. The sequences were highly conserved in contrast to the diversity observed between gH sequences from herpesviruses of different subgroups. Only four coding changes were present in any of the comparisons, and only one unique coding change was observed between the laboratory strains and the clinical isolate (Asp-168 to Gly). These sequences were compared with those of antigenic variants selected by antibody in tissue culture. Twelve variants were independently selected with antibody LP11 or 52S from parent strain SC16 or HFEM. For each variant, the gH nucleotide sequence was derived and a point mutation was identified giving rise to a single amino acid substitution. The LP11-resistant viruses encoded gH sequences with amino acid substitutions at sites distributed over one-half of the gH external domain, Glu-86, Asp-168, or Arg-329, while the 52S-resistant mutant viruses had substitutions at adjacent positions Ser-536 and Ala-537. One LP11 mutant virus had a point mutation in the gH gene that was identical to that of the clinical isolate, giving rise to a substitution of Asp-168 with Gly. Both LP11 and 52S appeared to recognize distinct gH epitopes as mutant virus resistant to neutralization and immunoprecipitation with LP11 remained sensitive to 52S and the converse was shown for the 52S-resistant mutant virus. This is consistent with previous studies which showed that while the 52S epitope could be formed in the absence of other virus products, virus gene expression was required for stable presentation of the LP11 epitope, and for transport of gH to the cell surface (Gompels and Minson, J. Virol. 63:4744-4755, 1989). All mutant viruses produced numbers of infectious particles that were similar to those produced by the wild-type virus, with the exception of one variant which produced lower yields.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707982      PMCID: PMC240591     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  The morphology of herpes virus.

Authors:  P WILDY; W C RUSSELL; R W HORNE
Journal:  Virology       Date:  1960-10       Impact factor: 3.616

Review 2.  Control of protein exit from the endoplasmic reticulum.

Authors:  H R Pelham
Journal:  Annu Rev Cell Biol       Date:  1989

3.  Conservation of gene organization in the lymphotropic herpesviruses herpesvirus Saimiri and Epstein-Barr virus.

Authors:  U A Gompels; M A Craxton; R W Honess
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus.

Authors:  D R Gretch; B Kari; L Rasmussen; R C Gehrz; M F Stinski
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

5.  The CaaX motif of lamin A functions in conjunction with the nuclear localization signal to target assembly to the nuclear envelope.

Authors:  D Holtz; R A Tanaka; J Hartwig; F McKeon
Journal:  Cell       Date:  1989-12-22       Impact factor: 41.582

6.  A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.

Authors:  N Miller; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

7.  Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation.

Authors:  C Cheng-Mayer; M Quiroga; J W Tung; D Dina; J A Levy
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

8.  Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI.

Authors:  D C Johnson; M C Frame; M W Ligas; A M Cross; N D Stow
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

9.  Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H.

Authors:  M P Cranage; G L Smith; S E Bell; H Hart; C Brown; A T Bankier; P Tomlinson; B G Barrell; T C Minson
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

10.  A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells.

Authors:  M W Ligas; D C Johnson
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

View more
  36 in total

1.  Glycoprotein H of pseudorabies virus is essential for entry and cell-to-cell spread of the virus.

Authors:  B Peeters; N de Wind; R Broer; A Gielkens; R Moormann
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Site-directed and linker insertion mutagenesis of herpes simplex virus type 1 glycoprotein H.

Authors:  M Galdiero; A Whiteley; B Bruun; S Bell; T Minson; H Browne
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Identification and characterization of the guinea-pig cytomegalovirus glycoprotein H gene.

Authors:  R C Brady; M R Schleiss
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

4.  Glycoprotein H of herpes simplex virus type 1 requires glycoprotein L for transport to the surfaces of insect cells.

Authors:  D F Westra; K L Glazenburg; M C Harmsen; A Tiran; A Jan Scheffer; G W Welling; T Hauw The; S Welling-Wester
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109.

Authors:  Ashley E Fouts; Laëtitia Comps-Agrar; Katharina F Stengel; Diego Ellerman; Allyn J Schoeffler; Søren Warming; Dan L Eaton; Becket Feierbach
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

6.  Identification and characterization of a novel structural glycoprotein in pseudorabies virus, gL.

Authors:  B G Klupp; J Baumeister; A Karger; N Visser; T C Mettenleiter
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complex.

Authors:  T Peng; M Ponce de Leon; M J Novotny; H Jiang; J D Lambris; G Dubin; P G Spear; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Scanning Mutagenesis of Human Cytomegalovirus Glycoprotein gH/gL.

Authors:  Eric P Schultz; Jean-Marc Lanchy; Erin E Ellerbeck; Brent J Ryckman
Journal:  J Virol       Date:  2015-12-09       Impact factor: 5.103

9.  Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL.

Authors:  Tirumala K Chowdary; Tina M Cairns; Doina Atanasiu; Gary H Cohen; Roselyn J Eisenberg; Ekaterina E Heldwein
Journal:  Nat Struct Mol Biol       Date:  2010-07-04       Impact factor: 15.369

10.  Localization of the Interaction Site of Herpes Simplex Virus Glycoprotein D (gD) on the Membrane Fusion Regulator, gH/gL.

Authors:  Tina M Cairns; Doina Atanasiu; Wan Ting Saw; Huan Lou; J Charles Whitbeck; Noah T Ditto; Birgitte Bruun; Helena Browne; Lucas Bennett; Chun Wu; Claude Krummenacher; Benjamin D Brooks; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.